Daniel Carradice
1.8K posts
@DanielCarradice
Vascular Surgeon @HullHospitals Professor @HullYorkMed Vasc Surgical Specialty Lead @RCSnews Chair Venous Special Interest Group @VSGBI Tweets my opinions
1st newsletter for the @NIHRresearch RAVE RCT: lithotripsy vs. no lithotripsy in calcified #PAD lesions - take part now!
Thank you @HSJ_Awards for the recognition! @VascularHull ,@chetter_ian ,@DanielCarradice,@seanpymer9 ,@prof_thakker
1st newsletter for the @NIHRresearch RAVE RCT: lithotripsy vs. no lithotripsy in calcified #PAD lesions - take part now!
🔍 Focused update - ESVS PAD Guidelines Recently published high-quality evidence, particularly the SWEDEPAD 2 trial, showed no meaningful quality-of-life benefit and raised concerns about possible long-term mortality with paclitaxel-coated devices, challenging prior assumptions about their net benefit. This prompted a focused update given the potential direct impact on patient safety and clinical decision-making in patients with intermittent claudication Read the article here: ejves.com/article/S1078-… @robhinchliffe1 @AWanhainen @VASCevidence
What’s happening in the Vascular Sector? Well, quite a lot actually. Today was the latest step in the journey to reforming the sector: our Annual Parliamentary Drop In. Friends and colleagues from across the sector met with MPs and Peers to chat all things vascular.
Big moment for our program. Thrilled to welcome three outstanding vascular surgery fellows to Carolinas Medical Center for 2027–2029. The growth reflects the strength of our training environment, mentorship, and case volume. The future is being built now.
